Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities
Cancers · 17.07.2026 · 18 (14) · 2315
DOI: 10.3390/cancers18142315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.07.2026. Verfasst von Noor Farhoud und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreatic malignancy accounting for approximately 1–2% of adult pancreatic neoplasms. Although historically grouped with pancreatic ductal adenocarcinoma (PDAC), accumulating evidence demonstrates that PACC represents a biologically distinct entity with unique clinical, pathologic, and molecular characteristics. Compared with PDAC, PACC more commonly presents as a large pancreatic mass, is less frequently associated with obstructive jaundice, and exhibits lower rates of KRAS mutations. Recent genomic studies have identified recurrent alterations involving DNA damage repair pathways, WNT/β-catenin signaling, and actionable kinase fusions, including BRAF and RAF1 rearrangements. In advanced disease, fluoropyrimidine- and platinum-based regimens appear to demonstrate greater activity than traditional gemcitabine-based approaches, although prospective comparative data are lacking. This review summarizes the current understanding of the epidemiology, clinical presentation, pathology, molecular landscape, treatment approaches, and prognostic factors associated with PACC. We highlight emerging opportunities for precision oncology and discuss ongoing challenges in the management of this uncommon pancreatic malignancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS 66205, USA.
- Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
- Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
ORCID-Profile: Joaquina Celebre Baranda, Wei Zhang, Ravi Kumar Paluri, Ashish Manne, Prasad Dandawate, Weijing Sun
Zitieren
APA
Farhoud, N., Al-Rajabi, R. M. T., Baranda, J. C., Li, H., Zhang, W., Paluri, R. K., Manne, A., Dandawate, P., Sun, W., & Kasi, A. (2026). Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities. Cancers, 18(14), 2315. https://doi.org/10.3390/cancers18142315
Vancouver
Farhoud N, Al-Rajabi RMT, Baranda JC, Li H, Zhang W, Paluri RK, et al. Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities. Cancers. 2026;18(14):2315. doi:10.3390/cancers18142315
BibTeX
@article{Farhoud2026,
author = {Farhoud, Noor and Al-Rajabi, Raed Moh'd Taiseer and Baranda, Joaquina Celebre and Li, Haoran and Zhang, Wei and Paluri, Ravi Kumar and Manne, Ashish and Dandawate, Prasad and Sun, Weijing and Kasi, Anup},
title = {Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2315},
doi = {10.3390/cancers18142315}
}
EUVIMED